Developing inhibitors that block NKX2.2 directly can prevent it from co-occupying EWSFLI1 target genes and partnering with EWSFLI1 to stabilize the fusion protein, thus providing a novel avenue for developing targeted ES treatments to tackle this highly aggressive and incurable pediatric cancer. Here, NKX2-2 is linked to cancer.